Degradable Organically-Derivatized Polyoxometalate with Enhanced Activity against Glioblastoma Cell Line

Abstract

High efficacy and low toxicity are critical for cancer treatment. Polyoxometalates (POMs) have been reported as potential candidates for cancer therapy. On accounts of the slow clearance of POMs, leading to long-term toxicity, the clinical application of POMs in cancer treatment is restricted. To address this problem, a degradable organoimido derivative of hexamolybdate is developed by modifying it with a cleavable organic group, leading to its degradation. Of note, this derivative exhibits favourable pharmacodynamics towards human malignant glioma cell (U251), the ability to penetrate across blood brain barrier and low toxicity towards rat pheochromocytoma cell (PC12). This line of research develops an effective POM-based agent for glioblastoma inhibition and will pave a new way to construct degradable anticancer agents for clinical cancer therapy.

Molybdenum Oxides – From Fundamentals to Functionality

“…Reproduced with permission. [186] ] Copyright 2016, Royal Society of Chemistry. d) Proposed mechanism for SERS enhancement of MoO 3-x and e) MoO 3-x @MoO 3 nanosheets.…”

“…[193] Hexamolybdates compounds are also potential candidates for cancer therapy. [186] Mo 6 O 18 (≡NC 6 H 4 -2-CH 3 -6-CON(Cy)-CO-NH-Cy)] 2− compound has been used for the study of the human malignant glioma cell (U251). Its ability to penetrate across blood brain barrier and low toxicity towards rat pheochromocytoma cell (PC12) have been shown in Figure 20c, leading to new degradable anticancer agents that can potentially be used for clinical cancer therapies.…”

“…Its ability to penetrate across blood brain barrier and low toxicity towards rat pheochromocytoma cell (PC12) have been shown in Figure 20c, leading to new degradable anticancer agents that can potentially be used for clinical cancer therapies. [186]…”

Anticancer Activity of Polyoxometalate-Bisphosphonate Complexes: Synthesis, Characterization, In Vitro and In Vivo Results

“…16 A variant of this approach consists of grafting a cleavable group onto a hexamolybdate POM in order to improve degradability with one such hybrid POM being reported to exhibit good activity against human malignant glioma cells (U251, IC50~25 μM), the ability to penetrate the blood brain barrier, as well as low toxicity towards rat pheochromocytoma cells (PC12). 17 …”

Polyoxometalate entrapped caprolactam gels and their cytotoxicity study

“…There are some limited reports, in which POMs have been encapsulated in some polymer matrix in order to reduce toxicity and improve biological activity. [17][18][19] So far, biopolymers like chitosan and starch are used for encapsulation and nano carriers of POMs. [20][21][22][23][24] In a recent study by Rejinold et al, a thermoresponsive polymer, chitosan-g-poly(Nvinylcaprolactam) is used for cancer drug delivery.…”